Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 4, 2018

Primary Completion Date

March 18, 2019

Study Completion Date

November 26, 2020

Conditions
Endometriosis
Interventions
DRUG

Vilaprisan (BAY1002670)

Intake orally, once daily

DRUG

Matching Placebo

Intake orally, once daily

Trial Locations (23)

1090

Universitätsklinikum AKH Wien, Vienna

4020

Kepler Universitätsklinikum Campus IV, Linz

8036

Medizinische Universität Graz, Graz

9500

KABEG Landeskrankenhaus Villach, Villach

20036

Office of Dr. James A. Simon, MD, Washington D.C.

27103

Unified Women's Clinical Research, Winston-Salem

28500

Satakunnan keskussairaala, Pori

28557

Unified Women's Clinical Research - Morehead City, Morehead City

32256

Solutions Through Advanced Research, Inc., Jacksonville

33435

Helix Biomedics, LLC, Boynton Beach

37126

A.O.U.I. Verona, Verona

70001

Southern Clinical Research Associates LLC, Metairie

K7L 2V7

Queen's University, Kingston

K1H 7W9

Ottawa Hospital-Riverside Campus, Ottawa

H4P 2S4

Clinique OVO, Montreal

602 00

Gynekologie MEDA s.r.o., Brno

326 00

GynCare MUDr. Michael Svec s.r.o., Pilsen

00510

VL-Medi Oy, Helsinki

060-0031

Tokeidai Memorial Clinic, Sapporo

920-8530

Ishikawa Prefectural Central Hospital, Kanazawa

861-8520

Japanese Red Cross Kumamoto Hospital, Kumamoto

930-8550

Toyama Prefectural Central Hospital, Toyama

20-093

Centrum Medyczne Chodzki, Lublin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY